BioAge Labs to Participate in Notable Investor Conferences
BioAge Labs, Inc. (NASDAQ: BIOA) is a pioneering clinical-stage biotechnology company dedicated to developing therapeutic solutions aimed at metabolic diseases while focusing on the biology of human aging. Recently, the company announced its participation in significant upcoming investor conferences that promise to shed light on its innovative strategies and product candidates.
Details of Upcoming Conferences
One of the key events BioAge will be involved in is Citi's 2025 Biopharma Back to School Conference, scheduled for a date in early September. The company's CEO, Kristen Fortney, PhD, along with CFO, Dov Goldstein, MD, will engage in a fireside chat. This session is set to take place on September 3, and both leaders are looking forward to answering questions and sharing insights regarding their product pipeline.
Fireside Chat Scheduled
This fireside chat will start at 3:15 PM EDT, where insights into the future of BioAge Labs and how they are navigating the industry will be discussed, and will include a Q&A segment, offering the audience a chance to delve deeper into the company’s strategies.
Another Major Platform: Morgan Stanley Conference
Following the Citi event, BioAge will also participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. This engagement is highlighted by another fireside chat featuring Kristen Fortney and Dov Goldstein on September 10. This chat is scheduled for 10:00 AM to 10:45 AM EDT, providing attendees with robust dialogues concerning the company's ambitious goals in metabolic therapy.
Accessing Webcasts
For those unable to attend in person, live webcasts will be available for both investor conferences. After the events, recordings will be accessible in the investor section of the BioAge Labs website, ensuring that stakeholders can catch up on the discussions and insights shared by the leadership. These replays will be archived for 30 days post-event, making it convenient for investors to stay informed.
About BioAge Labs
Founded with a mission to harness the power of aging biology, BioAge Labs is delving deep into the science of longevity and metabolic diseases. Their flagship product, BGE-102, is an oral small-molecule NLRP3 inhibitor that is showing promise in preclinical trials, especially for its efficacy as a treatment for obesity. Notably, BGE-102 has exhibited significant weight loss results in early models, both in isolation and combined with GLP-1 receptor agonists.
Continuing Development
The company is currently advancing its Phase 1 SAD/MAD trial of BGE-102, with preliminary data expected by the year’s end. Additionally, the development of long-acting injectable and oral small molecule APJ agonists for obesity is underway, further broadening their product line as they strive to tackle metabolic aging.
Contact Information
For further inquiries, BioAge Labs has provided specific contacts for different segments: Chris Patil for Public Relations via email at media@bioagelabs.com, Dov Goldstein for Investor Relations at ir@bioagelabs.com, and a dedicated email for partnering inquiries at partnering@bioagelabs.com. Visit their website for more information about their innovative work in biotechnology.
Frequently Asked Questions
What is BioAge Labs known for?
BioAge Labs specializes in developing therapies for metabolic diseases by examining the biology of human aging.
When are the upcoming investor conferences?
The upcoming investor conferences are on September 3 at Citi's conference and September 10 at Morgan Stanley's conference.
How can I access the presentations?
The presentations will be available via live webcasts, with recordings archived on the BioAge Labs investor website for 30 days post-event.
What is BGE-102?
BGE-102 is BioAge Labs' lead therapeutic candidate, a brain-penetrant small-molecule NLRP3 inhibitor targeting obesity.
How can I contact BioAge Labs?
Interested parties can contact BioAge Labs through their designated email addresses for media, investor relations, and partnership inquiries.